What is the 13F Pro Quality Score for AVAH?

13F Pro ranks Aveanna Healthcare Holdings, Inc. (AVAH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AVAH's current score at https://13fpro.ai/company/AVAH (free sign-up required for the full ranking).

Where does 13F Pro source AVAH data?

All Aveanna Healthcare Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Aveanna Healthcare Holdings, Inc. files with the SEC under CIK 1832332. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AVAH in?

Aveanna Healthcare Holdings, Inc. (AVAH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives AVAH's revenue?

Per Aveanna Healthcare Holdings, Inc.'s latest 10-Q filed with the SEC on 2026-08-13, the biggest revenue drivers are: Private Duty Services (PDS) ($553.9M, +14.0% YoY); Home Health & Hospice (HHH) ($69.0M, +14.8% YoY); Medical Solutions (MS) ($47.5M, +9.4% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/AVAH.

What are AVAH's largest expenses?

Aveanna Healthcare Holdings, Inc.'s latest 10-Q reports these as the largest expense items: Cost of revenue, excluding depreciation and amortization ($452.0M, +19.3% YoY); Branch and regional administrative expenses ($97.1M, +7.8% YoY); Interest expense, net of interest income ($26.5M, -26.1% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended July 4, 2026).

How often is AVAH research updated on 13F Pro?

AVAH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Aveanna Healthcare Holdings, Inc.(AVAH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1832332 AVAH stock profile & AI dashboard →

13F Pro Quality Score

65.6/100

Rank #473 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

72.6/100

Profitability

73.5/100

Balance Sheet

92.0/100

Earnings Quality

57.7/100

Free Cash Flow

46.3/100

Institutional Flow

45.0/100

Revenue Scale

67.3/100

Dilution Risk

56.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why AVAH Scores 66/100

exact factor attribution · 2026-09-11

AVAH's composite is driven by revenue growth and capital efficiency. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+4.5 pts

73th pct

Capital efficiency

+4.2 pts

92th pct

Profitability

+3.5 pts

74th pct

Scale

+2.6 pts

67th pct

Earnings quality

+0.8 pts

58th pct

Earnings growth

+0.5 pts

59th pct

Shareholder dilution

+0.3 pts

56th pct

Institutional flow

-0.3 pts

45th pct

Free cash flow

-0.6 pts

46th pct

Latest change (2026-08-13): 59 → 60 · ↑ Earnings growth 30→99; despite ↓ Revenue growth 71→59

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

AVAH Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Aveanna Healthcare Holdings, Inc. (AVAH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AVAH at 65.6/100 on a 32-signal composite quality model, placing it at rank #473 of 2,961 stocks — the top 25% of the AI-ranked universe. AVAH scores in the top quartile across balance sheet strength (92.0). Based on the latest XBRL financial filings (Q2 2026), Aveanna Healthcare Holdings, Inc. reports quarterly revenue of $670.5M, net income of $40.3M, an operating margin of 11.9%. Top institutional holders of AVAH by reported 13-F value include BAIN CAPITAL INVESTORS, J.H. Whitney Equity Partners VII, Nut Tree Capital Management, based on the most recent SEC filings. AVAH trades on the Nasdaq exchange and files with the SEC under CIK 1832332. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVAH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aveanna Healthcare Holdings, Inc. directly from SEC EDGAR. Aveanna Healthcare Holdings, Inc.'s 13F Pro composite quality score has ranged between 30 and 66 since 2022, currently 65.6 — an improving long-term trajectory across 64 quarterly and live scoring snapshots.

What's Driving AVAH's Business? Latest 10-Q Breakdown

AI-extracted from Aveanna Healthcare Holdings, Inc.'s 10-Q filed 2026-08-13 — Q2 FY2026 (quarter ended July 4, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Biggest Revenue Drivers

Private Duty Services (PDS)$553.9M+14.0% YoY

12.3% volume growth in demand for non-clinical services and acquisitions, plus 1.7% revenue rate increase from Medicaid rate hikes and improved implicit price concessions.

Home Health & Hospice (HHH)$69.0M+14.8% YoY

18.5% increase in total episodes; home health episodic mix improved to 81.0% from 74.5% prior year.

Biggest Revenue Drivers

Total revenue: $670.5M+13.7% YoY

Private Duty Services (PDS)$553.9M+14.0% YoY

12.3% volume growth in demand for non-clinical services and acquisitions, plus 1.7% revenue rate increase from Medicaid rate hikes and improved implicit price concessions.

Home Health & Hospice (HHH)$69.0M+14.8% YoY

18.5% increase in total episodes; home health episodic mix improved to 81.0% from 74.5% prior year.

Medical Solutions (MS)$47.5M+9.4% YoY

4.4% volume growth and 5.0% revenue rate increase.

Largest Expense Items

Cost of revenue, excluding depreciation and amortization$452.0M+19.3% YoY

Higher caregiver labor costs including pass-through of reimbursement rate increases; higher general and professional liability reserves; Q2 2025 included $6.2M release of legal settlements not recurring.

Branch and regional administrative expenses$97.1M+7.8% YoY

Additional branch operations from Thrive and Family First acquisitions and costs to integrate acquired operations.

Interest expense, net of interest income$26.5M-26.1% YoY

Lower U.S. federal funds rate, May 2026 credit facility repricing reducing margins by 75bp, and refinancing benefit reduced weighted average rate from 9.0% to 6.6%.

Acquisition-related costs$4.4M+29.1% YoY

Costs associated with Family First acquisition completed June 1, 2026.

Watch Items from the Filing

PDS cost of revenue rate increased 7.8% YoY, outpacing 1.7% revenue rate growth, compressing spread rate 11.1%. Management attributes this to higher caregiver labor costs and liability reserves; sustained cost pressure could limit margin expansion.
Medicaid MCO represents 59.4% of total revenue. Management notes risks from changes to Medicaid under the One Big Beautiful Bill Act and downward pressure from Medicare Advantage plan proliferation.
Company completed $173.7M cash acquisition of Family First on June 1, 2026, funded from cash on hand. Goodwill of $156.2M recognized; integration costs ongoing. DSO stable at 45.5 days.
Outstanding variable rate debt of $1.5B as of July 4, 2026 with interest rate caps on $1.4B notional. Unhedged exposure of $83.4M would see interest expense increase $2.7M annually per 100bp rate rise.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$670.5M

Net Income

Q2 2026

$40.3M

Operating Margin

Q2 2026

11.9%

ROIC

Q2 2026

20.0%

D/E Ratio

Q2 2026

4.56

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+20.2% YoY

$2.43BFY 2025

FY22 $1.79BFY23 $1.90BFY24 $2.02BFY25 $2.43B

Net Income

+2159.1% YoY

$225.0MFY 2025

FY22 $-662.0MFY23 $-134.5MFY24 $-10.9MFY25 $225.0M

Operating Income

+83.5% YoY

$256.5MFY 2025

FY22 $-642.3MFY23 $8.1MFY24 $139.8MFY25 $256.5M

EPS (Diluted)

+1850.0% YoY

$1.05FY 2025

FY22 $-3.57FY23 $-0.71FY24 $-0.06FY25 $1.05

Total Assets

+21.0% YoY

$2.01BFY 2025

FY22 $1.71BFY23 $1.61BFY24 $1.66BFY25 $2.01B

Total Debt

+1.8% YoY

$1.31BFY 2025

FY22 $1.30BFY23 $1.29BFY24 $1.29BFY25 $1.31B

Op. Cash Flow

+285.6% YoY

$125.9MFY 2025

FY22 $-48.4MFY23 $22.7MFY24 $32.6MFY25 $125.9M

Free Cash Flow

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.43B +20.2%	$2.02B +6.8%	$1.90B +6.0%	$1.79B +6.5%	$1.68B +12.3%	$1.50B
Net Income	$225.0M +2159.1%	$-10.9M +91.9%	$-134.5M +79.7%	$-662.0M -465.6%	$-117.0M -105.2%	$-57.0M
Operating Income	$256.5M +83.5%	$139.8M +1631.8%	$8.1M +101.3%	$-642.3M -1678.6%	$-36.1M -935.6%	$-3.5M
EPS (Diluted)	$1.05 +1850.0%	$-0.06 +91.5%	$-0.71 +80.1%	$-3.57 -417.4%	$-0.69	—
Total Assets	$2.01B +21.0%	$1.66B +3.1%	$1.61B -5.8%	$1.71B -26.7%	$2.33B +26.6%	$1.84B
Total Debt	$1.31B +1.8%	$1.29B -0.4%	$1.29B -0.4%	$1.30B +4.5%	$1.24B +5.1%	$1.18B
Operating Cash Flow	$125.9M +285.6%	$32.6M +44.0%	$22.7M +146.8%	$-48.4M -326.4%	$-11.3M -109.7%	$116.6M
Free Cash Flow	—	—	—	—	$-27.3M -126.9%	$101.4M

Get alerted when AVAH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Aveanna Healthcare Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AVAH

BAIN CAPITAL INVESTORS LLC
$699.3M81,600,880 sh
J.H. Whitney Equity Partners VII, LLC
$231.9M27,061,967 sh
Nut Tree Capital Management, LP
$110.7M12,922,649 sh
BlackRock, Inc.
$63.5M7,410,053 sh
Ophir Asset Management Pty Ltd
$43.7M5,100,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$31.5M3,673,218 sh
BRAIDWELL LP
$26.3M3,065,106 sh
Boston Partners
$24.9M2,870,979 sh
CITADEL ADVISORS LLC
$19.6M2,285,756 sh
DIMENSIONAL FUND ADVISORS LP
$19.3M2,257,684 sh

Fund	Value	Shares
BAIN CAPITAL INVESTORS LLC	$699.3M	81,600,880
J.H. Whitney Equity Partners VII, LLC	$231.9M	27,061,967
Nut Tree Capital Management, LP	$110.7M	12,922,649
BlackRock, Inc.	$63.5M	7,410,053
Ophir Asset Management Pty Ltd	$43.7M	5,100,000
VANGUARD CAPITAL MANAGEMENT LLC	$31.5M	3,673,218
BRAIDWELL LP	$26.3M	3,065,106
Boston Partners	$24.9M	2,870,979
CITADEL ADVISORS LLC	$19.6M	2,285,756
DIMENSIONAL FUND ADVISORS LP	$19.3M	2,257,684

Companies Similar to AVAH

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

AMRX

Amneal Pharmaceuticals, Inc.

AI score

Similar quality profile · 11 shared holders

Hillsdale Investment Management Inc.Parkman Healthcare Partners LLC NFJ INVESTMENT GROUP, LLC

ANIP

ANI PHARMACEUTICALS INC

AI score

Similar quality profile · 13 shared holders

Parkman Healthcare Partners LLC Sio Capital Management, LLC NFJ INVESTMENT GROUP, LLC

GRDN

Guardian Pharmacy Services, Inc.

AI score

Similar quality profile · 7 shared holders

Boston Partners Ghisallo Capital Management LLC Jackson Creek Investment Advisors LLC

CON

Concentra Group Holdings Parent, Inc.

AI score

Similar quality profile · 8 shared holders

First Eagle Investment Management, LLC WESBANCO BANK INC EntryPoint Capital, LLC

EYE

National Vision Holdings, Inc.

AI score

Similar quality profile · 8 shared holders

Boston Partners EMERALD ADVISERS, LLC EMERALD MUTUAL FUND ADVISERS TRUST

ALHC

Alignment Healthcare, Inc.

AI score

Similar quality profile · 11 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Integrated Quantitative Investments LLC Cinctive Capital Management LP

NVST

Envista Holdings Corp

AI score

Similar quality profile · 11 shared holders

Boston Partners First Eagle Investment Management, LLC Parkman Healthcare Partners LLC

PODD

INSULET CORP

AI score

Similar quality profile · 4 shared holders

Parkman Healthcare Partners LLC SEGALL BRYANT & HAMILL, LLC Voleon Capital Management LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AVAH on your watchlist

Track score changes the day Aveanna Healthcare Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AVAH a good stock to buy?

13F Pro's AI-powered analysis of Aveanna Healthcare Holdings, Inc. (AVAH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AVAH are available on the AVAH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AVAH is classified as a mid company.

Which hedge funds own AVAH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AVAH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aveanna Healthcare Holdings, Inc.'s investment landscape.